Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
48
resultados
Última actualización
11/06/2026 [06:45:00]
Resumen de: WO2025027003A1
The disclosure provides methods for treating peripheral T-cell lymphoma (PTCL) using an anti-CD38 T-cell engager, as well as uses, compositions, and kits related thereto.
Resumen de: EP4755394A1
0001 Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and/or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.
Resumen de: EP4755921A1
Provided are a chimeric antigen receptor, and a GPRC5D antibody-containing chimeric antigen receptor and use thereof. The chimeric antigen receptor includes: an extracellular domain, capable of binding to a tumor antigen; a transmembrane domain, linked to the extracellular domain, the transmembrane domain being from a type I transmembrane protein or is an artificially synthesized transmembrane protein with a hydrophobic helix; and an intracellular domain, linked to the transmembrane domain. The tumor antigen is a tumor-specific antigen or a tumor-associated antigen. The amino acid sequence of the transmembrane domain is optimized, thereby providing the chimeric antigen receptor containing the GPRC5D antibody and an engineered immune cell. The engineered immune cell obtained based on the GPRC5D antibody exhibits a specific killing activity against multiple myeloma.
Resumen de: WO2025030174A1
Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, in treating a subject suffering from myelodysplastic syndromes (MDS), and in slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).
Resumen de: WO2026114115A1
A drug linker, and an antibody-drug conjugate thereof, a preparation method therefor and the use thereof. The drug linker and the antibody-drug conjugate have structures as represented by formula (I) and formula (II), respectively. The prepared antibody-drug conjugate has a targeted killing effect on breast cancer, gastric cancer, lung cancer (for example, non-small cell lung cancer, and specifically, lung adenocarcinoma), colon cancer, or lymphoma.
Resumen de: AU2024398914A1
The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.
Resumen de: AU2024364448A1
The present invention relates to compounds of formula (A) as DUX4 inhibitors for the treatment of e.g. neuromuscular disorders, inflammatory disorders, facioscapulohumeral muscular dystrophy, B-cell leukemia, sarcomas, solid cancers, rheumatoid arthritis, axial spondylarthritis, viral infections, mononucleosis, encephalitis, and varicella. Exemplary compounds are e.g.
Resumen de: US20260151399A1
The instant invention relates to combinations of an LSD1 inhibitor (or a pharmaceutically acceptable salt thereof) and a Menin inhibitor (or a pharmaceutically acceptable salt thereof). The combinations are particularly useful for treating cancer, including hematological cancers, such as acute myeloid leukemia or myelodysplastic syndrome.
Resumen de: US20260151482A1
Provided herein are adoptive cell therapy methods involving the administration of genetically engineered cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for selecting and treating subjects with multiple myeloma (MM).
Resumen de: US20260151503A1
0000 A targeted nanoscale particle is bound to the outer surface of the targeted cell, and is composed of a plurality of proteins interconnected via a first binding site. The targeted nanoscale particle further comprises a second binding site, and is bound to the outer surface of a target cell via the second binding site. In an exemplary embodiment, the targeted nanoscale particle can promote the interaction between the two types of cells by simultaneously binding to a chimeric antigen receptor T cell and a leukemia cell, thereby promoting the recognition and killing of the leukemia cell by the chimeric antigen receptor T cell. In addition, the internal cavities of the proteins in the targeted nanoscale particle provide space for loading of a chemotherapeutic drug, thus realizing the combination therapy of the chimeric antigen receptor T cell and other therapies while loading the drug.
Resumen de: EP4751778A2
0001 Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Resumen de: EP4752227A2
0001 The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
Resumen de: EP4751723A2
0001 Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myelodysplastic syndrome. Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myelodysplastic syndrome.
Resumen de: MX2026004901A
A container for holding one or more products. The container can comprise a bottom panel and a sidewall extending at least upwardly from the bottom panel and extending at least partially around an interior of the container. The sidewall can comprise at least an end panel, a comer panel, and a side panel. A flange can extend outwardly from the sidewall. The flange can comprise at least an end flange portion foldably connected to the end panel, a side flange portion foldably connected to the side panel, and a corner flange portion foldably connected to the comer panel. An extension can extend from each of the end flange portion and the side flange portion, and the comer flange portion can be in an overlapping relationship with each of the extensions for reinforcing the flange.A container for holding one or more products. The container can comprise a bottom panel and a sidewall extending at least upwardly from the bottom panel and extending at least partially around an interior of the container. The sidewall can comprise at least an end panel, a comer panel, and a side panel. A flange can extend outwardly from the sidewall. The flange can comprise at least an end flange portion foldably connected to the end panel, a side flange portion foldably connected to the side panel, and a corner flange portion foldably connected to the comer panel. An extension can extend from each of the end flange portion and the side flange portion, and the comer flange portion can be in an overlapping
Resumen de: MX2026004902A
The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.
Resumen de: MX2026005569A
The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.
Resumen de: MX2026003156A
The present disclosure provides compositions comprising Pralatrexate for subcutaneous administration. The present disclosure also provides methods of administering the compositions comprising Pralatrexate, as disclosed herein, for the treatment of disease (e.g., lymphoma).
Resumen de: MX2026003757A
Described herein are Casitas B-lineage lymphoma (Cbl) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or condition associated with Cbl-b activity, such as cancers.
Resumen de: MX2026005044A
The present disclosure is directed to methods of treating, for example, newly diagnosed multiple myeloma.
Resumen de: US20260144862A1
The present invention relates to means and methods to prevent and/or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and/or EBV-induced diseases are prevented.
Resumen de: US20260146100A1
0000 The present disclosure provides multispecific anti-CD22/anti-4-1BB antigen-binding molecules comprising a first antigen-binding domain that binds specifically to CD22 and a second antigen-binding domain that binds specifically to 4-1BB. In certain embodiments, the molecules further comprise a third antigen-binding domain that binds 4-1BB. In certain embodiments, the molecules are multispecific antibodies or antigen-binding fragments thereof. In certain embodiments, the antibodies are useful in treating a CD22-associated disease or disorder (e.g., lymphoma).
Resumen de: WO2026112410A1
Disclosed are novel compounds for use in treating a proliferative disorder such as a cancer. Further disclosed are compositions comprising the novel compounds. Methods of using the disclosed compounds and compositions are further described. The methods include administering one or more of the disclosed compounds for treatment of various proliferative disorders, including an HRAS-driven cancer, a KRAS-driven cancer, a NRAS-driven cancer, Ewing sarcoma, B-cell acute lymphoblastic leukemia, leukemia, lung cancer, non-small cell lung cancer (NSCLC), solid tumor, breast cancer, triple-negative breast cancer (TNBC), hormone-resistant triple negative breast cancer. Further described are combination therapies in which a novel compound is administered in combination with one or more of a MEK inhibitor, a KRAS G12C inhibitor, or a Selective Estrogen Receptor Degrader (SERD) to an individual in need thereof.
Resumen de: WO2026111477A1
The present invention relates to a composition for cancer prevention, comprising a statin-based drug as an active ingredient, and disclosed is that a statin drug known for hyperlipidemia treatment may effectively prevent cancer progression. More specifically, a novel use of rosuvastatin is provided so as to enable providing a composition for multiple myeloma (MM) prevention for inhibiting progression from monoclonal gammopathy of undetermined significance (MGUS) to MM. In addition, the composition may exhibit a greater tumor growth inhibition effect when bortezomib and rosuvastatin are co-administered compared to when each medicine is administered alone.
Resumen de: WO2026110144A1
A computational system and method for digital modeling of cardiac cell membrane electrophysiology is disclosed. The system generates a digital model representing the cell membrane as a dielectric lipid bilayer comprising a capacitor element and a resistor element, where the resistor element is emulated by a plurality of ion channels. The system calculates cell membrane potential based on intracellular and extracellular concentrations of key ions, such as Na+, K+, Ca2+, and Cl-, using the Goldman-Hodgkin-Katz equation. Generation of cellular membrane action potentials is simulated by modeling the opening and closing of voltage-gated ion channels in response to triggering events. The model provides dynamic visualizations of the distinct phases of the action potential, including depolarization and repolarization, offering a high-fidelity tool for research and for enhancing the realism of training simulations in electrophysiology procedures.
Nº publicación: WO2026112609A1 28/05/2026
Solicitante:
INST FOR CANCER RESEARCH D/B/A THE RESEARCH INST OF FOX CHASE CANCER CENTER [US]
INSTITUTE FOR CANCER RESEARCH d/b/a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER
Resumen de: WO2026112609A1
The present disclosure is concerned with compounds that restore p53 activity and methods of using the compounds in the treatment of various disorders related to loss of p53 activity such as, for example, cancer (e.g., a sarcoma, a carcinoma, a head-and-neck cancer, hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
BOPI
Sede Electrónica
